Serum sickness-like reaction associated with efalizumab.


OBJECTIVE To report a case of serum sickness-like reaction (SSLR) possibly induced by efalizumab, a recombinant humanized immunoglobulin G1 kappa isotype monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis. CASE SUMMARY A 37-year-old woman with plaque psoriasis who had been treated with efalizumab for 2 months developed a… (More)
DOI: 10.1345/aph.1L495


Cite this paper

@article{AshrafBenson2009SerumSR, title={Serum sickness-like reaction associated with efalizumab.}, author={Sadia Ashraf-Benson and Geoffrey C Wall and Lisa A Veach}, journal={The Annals of pharmacotherapy}, year={2009}, volume={43 2}, pages={383-6} }